
Medicine and Health
Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia
M. E. Layton, J. C. Kern, et al.
Discover how the inhibition of Phosphodiesterase 10A (PDE10A) could revolutionize schizophrenia treatment by normalizing striatal activity. This exciting research conducted by Mark E Layton and colleagues unveils MK-8189, a powerful PDE10A inhibitor currently undergoing Phase 2b clinical development.
Playback language: English
Related Publications
Explore these studies to deepen your understanding of the subject.